Vera Therapeutics, Inc. $VERA is Eversept Partners LP’s Largest Position

Eversept Partners LP boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 9.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,072,304 shares of the company’s stock after buying an additional 264,468 shares during the quarter. Vera Therapeutics accounts for approximately 7.8% of Eversept Partners LP’s holdings, making the stock its biggest position. Eversept Partners LP owned approximately 4.39% of Vera Therapeutics worth $155,581,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Hudson Bay Capital Management LP raised its position in Vera Therapeutics by 47.4% in the 3rd quarter. Hudson Bay Capital Management LP now owns 440,591 shares of the company’s stock worth $12,804,000 after buying an additional 141,615 shares during the last quarter. UBS Group AG raised its position in Vera Therapeutics by 27.9% in the 4th quarter. UBS Group AG now owns 207,289 shares of the company’s stock worth $10,497,000 after buying an additional 45,214 shares during the last quarter. Schroder Investment Management Group raised its position in Vera Therapeutics by 82.4% in the 3rd quarter. Schroder Investment Management Group now owns 679,992 shares of the company’s stock worth $19,652,000 after buying an additional 307,243 shares during the last quarter. Vanguard Group Inc. raised its position in Vera Therapeutics by 6.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock worth $92,720,000 after buying an additional 189,545 shares during the last quarter. Finally, Braidwell LP purchased a new position in Vera Therapeutics in the 3rd quarter worth about $13,738,000. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

VERA has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price target on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. HC Wainwright upped their price target on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Finally, Evercore set a $91.00 price target on shares of Vera Therapeutics in a research report on Friday, May 15th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Vera Therapeutics Price Performance

NASDAQ VERA opened at $35.01 on Thursday. Vera Therapeutics, Inc. has a 52 week low of $19.07 and a 52 week high of $56.05. The firm has a market capitalization of $2.51 billion, a P/E ratio of -6.32 and a beta of 0.93. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. The company has a 50-day moving average price of $36.63 and a 200-day moving average price of $41.52.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the firm earned ($0.81) EPS. Equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Activity

In related news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at approximately $10,362,498.20. The trade was a 8.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.